Influence of baseline severity on antidepressant efficacy for anxiety disorders: Meta-analysis and meta-regression

British Journal of Psychiatry

Volumn 208, Issue 6, 2016, Pages 515-521

  De Vries, Ymkje Anna ^a   De Jonge, Peter ^a   Van Heuvel, Edwin Den ^b   Turner, Erick H ^c   Roest, Annelieke M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO;

ANXIETY DISORDER; DISEASE SEVERITY; DRUG EFFICACY; GENERALIZED ANXIETY DISORDER; HUMAN; META ANALYSIS; OBSESSIVE COMPULSIVE DISORDER; PANIC; POSTTRAUMATIC STRESS DISORDER; PRACTICE GUIDELINE; PREDICTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCORING SYSTEM; SHORT COURSE THERAPY; SOCIAL PHOBIA; ANXIETY DISORDERS; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; HUMANS; SEVERITY OF ILLNESS INDEX;

EID: 84973512751     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.115.173450     Document Type: Review

References (37)

1. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 617-27.
2. Kessler RC, Berglund PA, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593-603.
3. Penninx BWJH, Nolen WA, Lamers F, Zitman FG, Smit JH, Spinhoven P, et al. Two-year course of depressive and anxiety disorders: results from the Netherlands Study of Depression and Anxiety (NESDA). J Affect Disord 2011; 133: 76-85.
4. Bruce SE, Yonkers KA, Otto MW, Eisen JL, Weisberg RB, Pagano M, et al. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry 2005; 162: 1179-87.
5. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013; 382: 1575-86.
6. Hidalgo RB, Tupler LA, Davidson JRT. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol 2007; 21: 864-72.
7. Hansen RA, Gaynes BN, Gartlehner G, Moore CG, Tiwari R, Lohr KN. Efficacy and tolerability of second-generation antidepressants in social anxiety disorder. Int Clin Psychopharmacol 2008; 23: 170-9.
8. Soomro GM, Altman DG, Rajagopal S, Oakley Browne M. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev 2008; 1: CD001765.
9. Stein DJ, Ipser JC, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev 2006; 1: CD002795.
10. Andrisano C, Chiesa A, Serretti A. Newer antidepressants and panic disorder: a meta-analysis. Int Clin Psychopharmacol 2013; 28: 33-45.
11. Khan A, Leventhal RM, Khan SRF, Brown WA. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol 2002; 22: 40-5.
12. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008; 5: e45.
13. Barbui C, Cipriani A, Patel V, Ayuso-Mateos JL, van Ommeren M. Efficacy of antidepressants and benzodiazepines in minor depression: systematic review and meta-analysis. Br J Psychiatry 2011; 198: 11-6.
14. Khan A, Bhat A, Faucett J, Kolts RL, Brown WA. Antidepressant-placebo differences in 16 clinical trials over 10 years at a single site: role of baseline severity. Psychopharmacology (Berl) 2011; 214: 961-5.
15. Khan A, Brodhead AE, Kolts RL, Brown WA. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. J Psychiatr Res 2005; 39: 145-50.
16. Fournier JC, Derubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. Antidepressant drug effects and depression severity. JAMA 2010; 303: 47-53.
17. Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012; 69: 572-9.
18. Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol 2002; 22: 309-17.
19. Sugarman MA, Loree AM, Baltes BB, Grekin ER, Kirsch I. The efficacy of paroxetine and placebo in treating anxiety and depression: a meta-analysis of change on the Hamilton Rating Scales. PLoS One 2014; 9: e106337.
20. Stein DJ, Stein MB, Pitts CD. Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. J Clin Psychiatry 2002; 63: 152-5.
21. Montgomery SA. Implications of the severity of social phobia. J Affect Disord 1998; 50 (suppl 1): s17-22.
22. Pollack MH, Meoni P, Otto MW, Hackett D. Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short-and long-term studies. J Clin Psychopharmacol 2003; 23: 250-9.
23. Roest AM, de Jonge P, Williams CD, de Vries YA, Schoevers RA, Turner EH. Reporting bias in clinical trials investigating the efficacy of second-generation antidepressants in the treatment of anxiety disorders: a report of 2 metaanalyses. JAMA Psychiatry 2015; 72: 500-10.
24. Turner EH. How to access and process FDA drug approval packages for use in research. BMJ 2013; 347: f5992.
25. Morris SB, DeShon RP. Combining effect size estimates in meta-analysis with repeated measures and independent-groups designs. Psychol Methods 2002; 7: 105-25.
26. Adli M, Baethge C, Heinz A, Langlitz N, Bauer M. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 2005; 255: 387-400.
27. Ioannidis JPA, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. BMJ 2007; 335: 914-6.
28. Bandelow B, Reitt M, Rover C, Michaelis S, Gorlich Y, Wedekind D. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol 2015; 30: 183-92.
29. Hoskins M, Pearce J, Bethell A, Dankova L, Barbui C, Tol WA, et al. Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis. Br J Psychiatry 2015; 206: 93-100.
30. Leucht S, Hierl S, Kissling W, Dold M, Davis JM. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry 2012; 200: 97-106.
31. Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry 2006; 59: 990-6.
32. Cuijpers P, Turner EH, Koole SL, van Dijke A, Smit F. What is the threshold for a clinically relevant effect? The case of major depressive disorders. Depress Anxiety 2014; 31: 374-8.
33. National Institute for Health and Care Excellence. Common Mental Health Disorders: Identification and Pathways to Care (Clinical Guideline CG123). NICE, 2011.
34. Baumeister H. Inappropriate prescriptions of antidepressant drugs in patients with subthreshold to mild depression: time for the evidence to become practice. J Affect Disord 2012; 139: 240-3.
35. Spijker J, de Graaf R, Bijl RV, Beekman ATF, Ormel J, Nolen WA. Duration of major depressive episodes in the general population: results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Br J Psychiatry 2002; 181: 208-13.
36. Hendriks SM, Spijker J, Licht CMM, Beekman ATF, Penninx BWJH. Two-year course of anxiety disorders: different across disorders or dimensions? Acta Psychiatr Scand 2013; 128: 212-21.
37. National Institute for Health and Care Excellence. Depression in Adults: Recognition and Management (Clinical Guideline CG90). NICE, 2009.